COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active…
1D
+2.9%
1W
-4.6%
1M
+23.0%
6M
+9.0%
YTD
+7.5%
1Y
-16.1%
2Y
-40.0%
5Y
-96.0%
10Y
-99.4%
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~21% weaker price swings than usual
0
STRONG BUY
4
BUY
1
HOLD
1
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 30/03/2022
P/E
-0.5
P/B
0.46
EV/EBITDA
-0.89
RETURN ON EQUITY
-1.3%
NET MARGIN
-6.4%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
99.4%
FLOAT SHARES
990,907
AVG. DAILY VOLUME (30D)
685
COSCIENS Biopharma Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Canada.
The CEO is Peter Harry Puccetti, the company employs around 28 people.
The IPO was on 18/09/1996; the stock trades on TSX under the ticker CSCI.TO.
6 analysts rate the stock, the consensus is Buy (as of 30/03/2022).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Yes. The last dividend was CA$0.00 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Comparable stocks include Helus Pharma, Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Bausch + Lomb, AbCellera Biologics, Eli Lilly and Company and Johnson & Johnson.
Clicking "Analyze stock" lets five strategies assess COSCIENS Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.